Research and Markets Releases 2022 Digital Biomarkers Drug Development Market Report
The "Growth Opportunities for Digital Biomarkers in Drug Development" report has been added to ResearchAndMarkets.com's offering. The study focuses on 3 major therapy areas, neurology, oncology, and cardiology, which digital biomarkers impact.
Key topics covered:
- Strategic Imperatives
- Growth Opportunity Analysis
- Growth Opportunity Analysis - Neurology
- Growth Opportunity Analysis - Oncology
- Regulatory Landscape
- Industry Assessment and Analysis
- Patent Landscape
- Growth Opportunity Universe
Read more about the report here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
